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Summary
In this studywe have examined theeffectsofinterleukin 10 (IL-10) on polymorphonuclearleukocytes
(PMN), and found that it is a potent inhibitor of tumor necrosis factor (TNF), IL-10, and IL-8
secretion triggered by lipopolysaccharide (LPS). Cytokine production by phagocytosing PMN
was also inhibited by IL-10, but to a lesser extent than the LPS-induced production. As shown
by Northern blot analysis, IL-10 diminished the levels of TNF, IL-1(3, and IL-8 mRNAs late
after the onsetof stimulation of PMN with LPS. In addition,we provideevidence that the kinetics
of LPS-induced IL-8 production by PMN is composed of two distinct phases. Specifically, our
experiments demonstrated that in the first phase, the production of IL-8 is a process directly
induced by LPS that lasts for some hours. After this early wave, a second phase begins that is
sustained and leads to an elevated production of IL-8 that appears to be due to the endogenous
release of TNF and IL-10. This second wave can in fact be blocked by anti-TNF and anti-IL-10
neutralizing antibodies, andby IL-10 as the consequence of its downregulatory effects on TNF
and IL-1/3 release. Taken together, these findings identify novel biological actions of IL-10 as
a suppressor of the inflammatory response.
Accumulation of PMN in tissues is a characteristic feature
1A of inflammation. PMN stimulates and amplifies addi-
tional migrationofcells, andonepossible mechanismby which
this occurs is the production of rytokines by the same PMN.
Evidence from a number oflaboratories (for areview see ref-
erence 1), has shown that PMN can synthesize a selective
range of cytokines when given the appropriate stimuli. Our
own in vitro studies demonstrated that, upon stimulation
with LPS, or after phagocytosis of yeast particles opsonized
with IgG (Y-IgG), PMN arecapable of expressing thegenes
and secreting newly synthesized IL-8 (2), TNF (3), and IL-
10 (4). Thesethree rytokines have a critical role in the regu-
lation of PMN recruitment, and also of many PMN func-
tions directed against the offending agent to be eliminated
(5-7).
IL-10 is a recently characterized cytokine (8, 9) that has
been implicated in the regulation of the functions of lym-
phoid andmyeloidcells (10) because ofits ability to suppress
the synthesis of proinflammatory cytokines from T cells (9)
andmonocytes/macrophages (11-13). In this study, we show
that IL-10is apotent inhibitor of proinflammatory cytokine
release by PMN stimulated with LPS, suggesting that IL-10
may also have an important regulatory role in limiting the
duration and extent of acute inflammatory response.
Materials and Methods
Cell Purification and Culture.
￿
Highly purified (>99.5%) PMN
were isolated underendotoxin-free conditions from buffy coatsof
healthy donors, as previously described (2-4). Immediately after
purification, PMN were suspended in RPMI-1640 medium sup-
plemented with 10% low endotoxin FCS (<0.006 ng/ml, Irvine
Scientific, SantaAna, CA)in thepresence or not ofpurified recom-
binant human IL-10 (kindly provided by Dr. K. Moore, DNAX
andSchering-Plough Corporation, Palo Alto, CA), andwere then
cultured at 37°C, either in 24-well tissue culture plates (Nunc,
Roskilde, Denmark) at 106/300 P.1, or in polystyrene flasks
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added to the cells at the following doses: 1 14g/ml LPS (fromEsche-
richia coli 026:136, purchased from SigmaChemical Co., St. Louis,
MO); 5 ng/ml TNF (purchased from Bachem Inc., Hannover, Ger-
many); 20 ng/ml IL-10 (obtained from Hazleton Laboratories,
Vienna, VA); and heat-killed yeast particles opsonized with IgG
(YIgG) at a particle/cell ratio of 2:1(2-4). In selected experiments,
neutralizing mAbs against TNF (1.154.2) (14) and IL-1f6 (609.9)
(15), and an isotype-matched control mAb for 13.154.2 and 609.9,
21110(16), were used. Cell-free supernatants for cytokine determi-
nation were harvested at predetermined times, spun at 2,000 rpm
for 30 s, and stored at -70°C.
RNA Isolation andNorthern Blot Analysis.
￿
Total RNA was ex-
tracted from PMN and analyzed as alreadydescribed (2-4). mRNAs
for TNF, IL-10,11-8, and actin, were detected by autoradiography
after hybridization of nylon filters with 3'P-labeled cDNA frag-
ments (Ready to go-DNA labelling kit; Pharmacia, Uppsala,
Sweden).
Cytokine Assays.
￿
Antigenic TNF was determined in the cell-
free supernatants by using a double-ligand immunoassay (50 pg/ml
detection limit)-{4). Extracellular antigenic IL-8 was measured by
a specific ELISA, having a detection limit of 20 pg/ml (2). IL-10
was determined by a double-determinant RIA developed with mAbs
609 and 206 (50 pg/ml detection limit) (4, 15).
Superoxide Anion (02-) Production.
￿
This was performed exactly
as described previously (17).
Statistical Analysis. Data are expressed as means ± SEM.
Statistical evaluationwas performed by the Student's t test forpaired
data and considered significant if p values were <0.05.
Results and Discussion
IL-10 Inhibits the Production of TNF, IL-1/3, and IL-8 by
Human PMN Stimulated with LPS. To determine whether
IL-10 had any effect on the neutrophil production of IL-8,
TNF, and IL-1f3, PMN were preincubated with IL-10 (100
U/ml) for 45 min and then stimulated with LPS for up to
18 h (Fig. 1). The accumulation of IL-8 upon LPS stimula-
tion was already significantly elevated after 2 h, increased
slightly over the next 4-6 h, and then rose dramatically up
to 18 h. TNF levels in response to LPS were detectable after
2 h, peaked at the 6-h time point, and thereafter decreased.
The first significant levels of IL-1f3 were detected at 3-4 h
and then continued to rise up to 18 h. This pattern ofcytokine
secretion by PMN was consistent with results previously
IL-8
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shown by us (2-4, 17), and by other investigators (18-21).
Even though after 2-3 h of LPS stimulation IL-10 did not
influence IL-8 release (5 t 3% inhibition, n = 8), at 6 h
it markedly suppressed the accumulation of IL-8 (by 44 ±
23%, p <0.05, n = 9), and even more at 18 h (by 69 ±
13%, p <0.05, n = 8) . Inhibition by IL-10 was greater if
calculated on the basis of the increased accumulation of IL-8
from 2 to 6 h (79 ± 20% inhibition, p <0.05, n = 7), or
from 6 to 18 h (86 ± 10% inhibition, p <0.05, n = 7) .
The production of TNF and IL-1f3 was almost completely
abrogated by IL-10 at all time points tested (Fig. 1). Results
similar to those just described were obtained in five other
experiments in which IL-10 was added to PMN at the same
time as LPS, and in two more in which LPS was used at
10 and 100 ng/ml (data not shown). Other studies indicated
that the inhibitory effects were dependent on the concentra-
tion ofIL-10 used: for IL-10, maximal inhibition was reached
upon exposure of LPS-stimulated PMN to 10 U/ml IL-10,
whereas for TNF and IL-8, maximal inhibition was reached
at 100 U/ml IL-10(data not shown). To understand whether
the inhibitory effect of IL-10 was selective for cytokine gener-
ation, we investigated the effect of IL-10 on neutrophil re-
spiratory burst. PMN were incubated for 4 and 18 h with
or without 100 U/ml IL-10, in the presence or not of IFN-y
and LPS, which are known to potentiate PMN respiratory
burst (22, 23). In these conditions, IL-10, contrary to what
has been observed with PMA-stimulated mouse macrophages
(13), did not significantly influence either the constitutive
or the enhanced capability of PMN to produce 02 - in re-
sponse to FMLP. Similar results were obtained if TNF was
used as an activating agent, or if PMA was used as a trig-
gering stimulus (data not shown).
Autocrine Role of TNFandIL-1f3for the LPS-stimulated IL-8
Production. Since IL-10 started to suppress the accumulation
of IL-8 only after 5-6 h (Fig. 1), we evaluated the possibility
that the inhibitory effect was the result of the suppression
ofTNF and IL-1,(3 secretion. Fig. 2 A shows that PMN were
able to release IL-8 after stimulation with TNF, and much
less with IL-1f3 (Fig. 2 B) . However, when TNF and IL-1l
were added to PMN in combination, at any concentrations,
including those observed to be released by LPS-stimulated
PMN, they produced an additive, if not often a synergistic,
effect on the release of IL-8 measured from 2 and up to 18 h
---w- LPS
-0- IG10+LPS
IL-1
Figure 1.
￿
Effect ofIL-10on LPS-
induced release of IL-8, TNF, and
IL-10 from PMN. PMN (106/300
Al) were preincubated with or
without 100 U/ml IL-10 for 45min
and then cultured for up to 18 h
after the addition of 1 Ftg/ml LPS.
Released cytokines into the cell-free
supernatants were measured by im-
munoassays as described in Mate-
rial and Methods. Shown are the
mean values ofduplicate assays from
a single representative experiment
out ofnine performed with similar
results.Figure 2 .
￿
CapabilityofTNF and
IL-1fl to induce the release of IL-8
from PMN, without being in-
hibited by IL-10 . (A) Time-course
of IL-8 release byPMN stimulated
with 5 ng/mlTNF in the presence
or absence of 100 U/ml IL-10 .
Shown are the mean values ± SEM
of duplicate assays for each time
point, obtained from four experi-
ments performed under the same
conditions. (B) Time-course ofIL-8
release induced byPMN stimulated
with 0 .5 ng/ml TNF in combina-
tionwithvarious concentrations of
IL-1#, in the presence or absence
of100 U/ml IL-10. Shown are the
mean values t SEM of duplicate
assays for each time point, obtained
from three experiments performed
under the same conditions . The
amounts of IL-8 released by un-
treated PMN were subtracted (<14
± 5 pg/ml). (C) Inhibition ofLPS-
induced IL-8 production by anti-
TNF and anti-IL-1/3 Abs . PMN
were stimulatedwith LPS (1 pg/ml)
for the indicated intervals, in the
presence ofeither IL-10, or ofanti-
TNF and anti-IL-1/3 neutralizing
Abs (10 Itg/ml), alone or in combination. Cell-free supernatants were then analyzed for IL-8 accumulation . Shown are the mean values t SEM of
percent inhibition exerted by the different agents on LPS-induced IL-8 production. Values at 18 h were calculated on thebasis of the increased accumula-
tion of IL-8 from 6 to 18 h. Data derive from these experiments .
of incubation (Fig . 2 B) . Remarkably, accumulation of IL-8
triggered by TNF, used alone (Fig. 2 A) or in combination
with IL-19 (Fig. 2 B), was unaffected by IL-10 . The effect
on IL-8 release of anti-TNF and anti-IL-1(3 neutralizing Abs
added to LPS-stimulated PMN either alone or in combina-
tion, was then investigated and compared with that of IL-
10 . After 2 (data not shown) or 6 h (Fig. 2 C), anti-TNF
and/or anti-IL-1/3 Abs did not significantly influence the ac-
cumulation of IL-8 stimulated by LPS. However, over the
remainder of the time course, the rise of IL-8 induced by
LPS was significantly reduced by anti-IL-1(3 and anti-TNF
Abs alone (by 25 ± 13% and 39 ± 11%, n = 3, respec-
tively), and especially by the combination of the two Abs
(by 64.5 ± 12%, n = 3) . This latter inhibition was com-
parable with that of IL-10 (81 ± 7%, n = 3) . Although
we cannot exclude the role of other endogenous factors pro-
duced in response to LPS, for example IL-lot (21), or of the
same IL-8 that induces itselfin an autoregulatory fashion (2),
collectively, these studies strongly indicate that the stimulus
for IL-8 release provided by LPS to PMN is divided in two
phases: an early one, directly induced by LPS itself and that
can be inhibited by IFN--y (24), and a late, prolonged one,
due to LPS-stimulated release of endogenous mediators, in-
cludingTNF and IL-19 which play a fundamental role . Ear-
lier observations in which IL-8 release by LPS-stimulated whole
blood was examined, also identified a biphasic pattern ofIL-8
production in that system, and attributed a mediating role
to endogenousTNF and IL-1(25) . The data reported herein
identify thePMN as one of the cell types responsible for this
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Figure 3.
￿
Effects of IL-10 on the modulation of cytokine gene expres-
sion induced by LPS on PMN . PMN were preincubated with or without
IL-10 for 45 min, before addition of LPS for the times indicated. Total
RNA was extracted and analyzed by Northern blot analysis. (A and B)
Two experiments performed with different donors, each representative of
three with similar results.
ReportTNF
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production, and strengthen the relationship between the en-
dogenous release ofTNF and IL-10 and the late wave of IL-8
release . Importantly, in conditions in which production of
TNF or IL-1(3 does not occur, as observed in the case ofFMLP-
stimulated PMN, the release of IL-8 peaks at 2-3 h and then
rapidly decreases to basal levels (17) .
E$ect ofIL-10 on Cytokine mRNA Accumulation Induced by
LPS To determine at which level IL-10 inhibited the produc-
tion of cytokines, Northern blot analyses were performed on
totalRNA isolated from PMN preincubated with IL-10 and
stimulated for different times with LPS . As shown in Fig.
3, and in agreement with previous observations (2-4, 17-21),
stimulation ofPMN with LPS resulted in enhancedmRNA
expression for TNF, IL-10, and IL-8 . To our surprise, IL-10
did not inhibit the LPS-induced upregulation of cytokine
mRNAs at their onset (2 h), but was effective at later time
points (>4 h) . These findings would suggest that the nega-
tive action of IL-10 on PMN cytokine production could be
attributed to different mechanisms, not necessarily mutually
exclusive : some acting, for example, at the level of cytokine
mRNA stability, or others acting at the level of cytokine trans-
lation or secretion . A recently published (26) extensive anal-
ysis on the mechanisms of the suppressive effects of IL-10
on the capacity ofmouse macrophages to produce TNF and
IL-1(3, would support our speculations .
Eyects ofIL-10 on TNF, IL-8, and IL-1aProducedafter Y-IgG
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Figure 4 . Effect of IL-10 on
YIgG phagocytosis-induced release
of IL-8, TNF, and IL-la . PMN
(106/300 Al) were preincubated
with or without IL-10 for 45 min
and then cultured for up to 18 h
in the presence of YIgG at a par-
ticle/cell ratio of 1:2. Shown -are the 0
￿
r
￿
18h
￿
mean values ofduplicate assays from
a single representative experiment
out offive performed with similar -
results.
Phagocytosis .
￿
Fig . 4 shows that IL-10 also decreasedY-IgG-
induced cytokine accumulation . The most suppressive effect
at 18 h was exerted on IL-10 (69 ± 12% inhibition, n =
4), whereas inhibitions of TNF (54 ± 18% inhibition,
n = 5) and IL-8 (27 ± 18% inhibition, n = 4) were less
pronounced, especially ifcompared with those obtained upon
LPS stimulation . At the level of gene expression, the effects
of IL-10 on themRNA steady state levels of the cytokines
under investigation were very similar to those described for
LPS (data not shown) . Together with the observations pre-
viously described (2-4), it is once again evident thatLPS and
Y-IgG phagocytosis affect PMN cytokine production by dis-
tinct pathways, and, in the case of Y-IgG-stimulated IL-8
production, the autocrine role played by TNF and IL-10 is
apparently not as determinant as for LPS.
In conclusion, the findings that IL-10 has a potent selec-
tive inhibitory effect on LPS-induced TNF, IL-10, and IL-8
production by human PMN, add new important properties
to the numerous biological effects exerted by IL-10 on leuko-
cytes (10), which could have clinical relevance . Recent data
(27, 28) indicated that pretreatment with IL-10 prevents the
toxicity of LPS in a murine model of endotoxic shock. Our
results would suggest that inhibition ofPMN cytokine produc-
tion, in addition to the suppression of monokines, could pre-
sumably contribute to IL-10-mediated protection from le-
thal endotoxemia.
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